White Blood Cell and Immunodeficiency Disorders

  • John F. Bastian
  • Michelle Hernandez
Part of the Molecular Pathology Library book series (MPLB, volume 4)


The human immune system comprises cellular and humoral elements that sense danger, and respond to threat in both nonspecific and antigen-specific ways that eliminate the offending agents and restore homeostasis. The innate immune system refers to those elements that recognize danger and activate the immune response. The cellular components of innate immunity include monocytes, dendritic cells, macrophages, mast cells, neutrophils, natural killer (NK) cells, and eosinophils. The humoral components include the complement proteins, C-reactive protein, and mannose lectin binding protein. In addition to activation of the immune system via cytokines and elaboration of effector molecules (such as interferons), some of the cells of the innate system process foreign antigen and present it to the adapative immune system. The adaptive immune system comprises the T and B cell compartments. Cytotoxic T cells kill infected cells; helper T cells provide support for the production of antibody by B cells; and regulatory T cells moderate the adaptive responses and prevent the emergence of autoimmunity. Primary immunodeficiencies derive from mutations in the genes involved in this elaborate host response. These mutations may occur at any phase of the immune response (i.e., from danger recognition to synthesis of high affinity antibody). The molecular consequences of these mutations lead to undue susceptibility to infection, autoimmunity, and, in some instances, malignancy.


Natural Killer Cell Chronic Granulomatous Disease Common Variable Immunodeficiency CVID Patient Leukocyte Adhesion Deficiency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Garibyan L, Lobito AA, Siegel RM, Call ME, Wucherpfennig KW, Geha RS. Dominant-negative effect of the heterozygous C104R TACI mutation in common variable immunodeficiency (CVID). J Clin Invest. 2007;117(6):1550–1557.CrossRefPubMedGoogle Scholar
  2. 2.
    Meechan DW, Maynard TM, Gopalakrishna D, Wu Y, LaMantia AS. When half is not enough: gene expression and dosage in the 22q11 deletion syndrome. Gene Expr. 2007;13(6):299–310.CrossRefPubMedGoogle Scholar
  3. 3.
    Heyworth PG, Cross AR, Curnutte JT. Chronic granulomatous disease. Curr Opin Immunol. 2003;15(5):578–584.CrossRefPubMedGoogle Scholar
  4. 4.
    Fischer A, Le Deist F, Hacein-Bey-Abina S, et al. Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol Rev. 2005;203:98–109.CrossRefPubMedGoogle Scholar
  5. 5.
    Sobacchi C, Marrella V, Rucci F, Vezzoni P, Villa A. RAG-dependent primary immunodeficiencies. Hum Mutat. 2006;27(12):1174–1184.CrossRefPubMedGoogle Scholar
  6. 6.
    Geha RS, Notarangelo LD, Casanova JL, et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol. 2007;120(4):776–794.CrossRefPubMedGoogle Scholar
  7. 7.
    Van De Wiele CJ, Vaughn JG, Blackburn MR, et al. Adenosine kinase inhibition promotes survival of fetal adenosine deaminase-deficient thymocytes by blocking dATP accumulation. J Clin Invest. 2002;110(3):395–402.Google Scholar
  8. 8.
    Kovanen PE, Leonard WJ. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol Rev. 2004;202:67–83.CrossRefPubMedGoogle Scholar
  9. 9.
    Vosshenrich CA, Ranson T, Samson SI, et al. Roles for common cytokine receptor gamma-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo. J Immunol. 2005;174(3):1213–1221.PubMedGoogle Scholar
  10. 10.
    Vosshenrich CA, Samson-Villeger SI, Di Santo JP. Distinguishing features of developing natural killer cells. Curr Opin Immunol. 2005;17(2):151–158.CrossRefPubMedGoogle Scholar
  11. 11.
    Recio MJ, Moreno-Pelayo MA, Kilic SS, et al. Differential biological role of CD3 chains revealed by human immunodeficiencies. J Immunol. 2007;178(4):2556–2564.PubMedGoogle Scholar
  12. 12.
    Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology. 6th ed. Philadelphia: Saunders/Elsevier; 2007.Google Scholar
  13. 13.
    Cunningham-Rundles C, Ponda PP. Molecular defects in T- and B-cell primary immunodeficiency diseases. Nat Rev Immunol. 2005;5(11):880–892.CrossRefPubMedGoogle Scholar
  14. 14.
    Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9(6):722–728.PubMedGoogle Scholar
  15. 15.
    Vetrie D, Vorechovsky I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361(6409):226–233.CrossRefPubMedGoogle Scholar
  16. 16.
    Yel L, Minegishi Y, Coustan-Smith E, et al. Mutations in the mu heavy-chain gene in patients with agammaglobulinemia. N Engl J Med. 1996;335(20):1486–1493.CrossRefPubMedGoogle Scholar
  17. 17.
    Minegishi Y, Coustan-Smith E, Wang YH, Cooper MD, Campana D, Conley ME. Mutations in the human lambda5/14.1 gene result in B cell deficiency and agammaglobulinemia. J Exp Med. 1998;187(1):71–77.CrossRefPubMedGoogle Scholar
  18. 18.
    Minegishi Y, Coustan-Smith E, Rapalus L, Ersoy F, Campana D, Conley ME. Mutations in Igalpha (CD79a) result in a complete block in B-cell development. J Clin Invest. 1999;104(8):1115–1121.CrossRefPubMedGoogle Scholar
  19. 19.
    Minegishi Y, Rohrer J, Coustan-Smith E, et al. An essential role for BLNK in human B cell development. Science. 1999;286(5446):1954–1957.CrossRefPubMedGoogle Scholar
  20. 20.
    Sawada A, Takihara Y, Kim JY, et al. A congenital mutation of the novel gene LRRC8 causes agammaglobulinemia in humans. J Clin Invest. 2003;112(11):1707–1713.PubMedGoogle Scholar
  21. 21.
    Kenter AL. Class-switch recombination: after the dawn of AID. Curr Opin Immunol. 2003;15(2):190–198.CrossRefPubMedGoogle Scholar
  22. 22.
    Papavasiliou FN, Schatz DG. Somatic hypermutation of immunoglobulin genes: merging mechanisms for genetic diversity. Cell. 2002;109(suppl):S35–S44.CrossRefPubMedGoogle Scholar
  23. 23.
    Aruffo A, Farrington M, Hollenbaugh D, et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell. 1993;72(2):291–300.CrossRefPubMedGoogle Scholar
  24. 24.
    Ferrari S, Giliani S, Insalaco A, et al. Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci U S A. 2001;98(22):12614–12619.CrossRefPubMedGoogle Scholar
  25. 25.
    Imai K, Slupphaug G, Lee WI, et al. Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat Immunol. 2003;4(10):1023–1028.CrossRefPubMedGoogle Scholar
  26. 26.
    Revy P, Muto T, Levy Y, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell. 2000;102(5):565–575.CrossRefPubMedGoogle Scholar
  27. 27.
    Knight AK, Cunningham-Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev. 2006;5(2):156–159.CrossRefPubMedGoogle Scholar
  28. 28.
    Vorechovsky I, Cullen M, Carrington M, Hammarstrom L, Webster AD. Fine mapping of IGAD1 in IgA deficiency and common variable immunodeficiency: identification and characterization of haplotypes shared by affected members of 101 multiple-case families. J Immunol. 2000;164(8):4408–4416.PubMedGoogle Scholar
  29. 29.
    Wu Y, Bressette D, Carrell JA, et al. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem. 2000;275(45):35478–35485.CrossRefPubMedGoogle Scholar
  30. 30.
    Castigli E, Wilson SA, Garibyan L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet. 2005;37(8):829–834.CrossRefPubMedGoogle Scholar
  31. 31.
    Salzer U, Chapel HM, Webster AD, et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet. 2005;37(8):820–828.CrossRefPubMedGoogle Scholar
  32. 32.
    van Zelm MC, Reisli I, van der Burg M, et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 2006;354(18):1901–1912.CrossRefPubMedGoogle Scholar
  33. 33.
    Losi CG, Silini A, Fiorini C, et al. Mutational analysis of human BAFF receptor TNFRSF13C (BAFF-R) in patients with common variable immunodeficiency. J Clin Immunol. 2005;25(5):496–502.CrossRefPubMedGoogle Scholar
  34. 34.
    Farrington M, Grosmaire LS, Nonoyama S, et al. CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency. Proc Natl Acad Sci U S A. 1994;91(3):1099–1103.CrossRefPubMedGoogle Scholar
  35. 35.
    Kanegane H, Tsukada S, Iwata T, et al. Detection of Bruton’s tyrosine kinase mutations in hypogammaglobulinaemic males registered as common variable immunodeficiency (CVID) in the Japanese Immunodeficiency Registry. Clin Exp Immunol. 2000;120(3):512–517.CrossRefPubMedGoogle Scholar
  36. 36.
    Morra M, Silander O, Calpe S, et al. Alterations of the X-linked lymphoproliferative disease gene SH2D1A in common variable immunodeficiency syndrome. Blood. 2001;98(5):1321–1325.CrossRefPubMedGoogle Scholar
  37. 37.
    Spickett GP, Farrant J, North ME, Zhang JG, Morgan L, Webster AD. Common variable immunodeficiency: how many diseases? Immunol Today. 1997;18(7):325–328.CrossRefPubMedGoogle Scholar
  38. 38.
    Casanova JL, Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol. 2002;20:581–620.CrossRefPubMedGoogle Scholar
  39. 39.
    Jouanguy E, Lamhamedi-Cherradi S, Lammas D, et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat Genet. 1999;21(4):370–378.CrossRefPubMedGoogle Scholar
  40. 40.
    Dorman SE, Holland SM. Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev. 2000;11(4):321–333.CrossRefPubMedGoogle Scholar
  41. 41.
    Altare F, Durandy A, Lammas D, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science. 1998;280(5368):1432–1435.CrossRefPubMedGoogle Scholar
  42. 42.
    Picard C, Fieschi C, Altare F, et al. Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds. Am J Hum Genet. 2002;70(2):336–348.CrossRefPubMedGoogle Scholar
  43. 43.
    Dupuis S, Dargemont C, Fieschi C, et al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science. 2001;293(5528):300–303.CrossRefPubMedGoogle Scholar
  44. 44.
    Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab. 2006;91(8):2843–2850.CrossRefPubMedGoogle Scholar
  45. 45.
    Anderson MS, Venanzi ES, Klein L, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science. 2002;298(5597):1395–1401.CrossRefPubMedGoogle Scholar
  46. 46.
    Anderson MS, Venanzi ES, Chen Z, Berzins SP, Benoist C, Mathis D. The cellular mechanism of Aire control of T cell tolerance. Immunity. 2005;23(2):227–239.CrossRefPubMedGoogle Scholar
  47. 47.
    Derbinski J, Gabler J, Brors B, et al. Promiscuous gene expression in thymic epithelial cells is regulated at multiple levels. J Exp Med. 2005;202(1):33–45.CrossRefPubMedGoogle Scholar
  48. 48.
    Powell BR, Buist NR, Stenzel P. An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy. J Pediatr. 1982;100(5):731–737.CrossRefPubMedGoogle Scholar
  49. 49.
    Bettelli E, Dastrange M, Oukka M. Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci U S A. 2005;102(14):5138–5143.CrossRefPubMedGoogle Scholar
  50. 50.
    Hori S, Takahashi T, Sakaguchi S. Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv Immunol. 2003;81:331–371.CrossRefPubMedGoogle Scholar
  51. 51.
    Chatila TA. Role of regulatory T cells in human diseases. J Allergy Clin Immunol. 2005;116(5):949–959. quiz 960.CrossRefPubMedGoogle Scholar
  52. 52.
    Owen CJ, Jennings CE, Imrie H, et al. Mutational analysis of the FOXP3 gene and evidence for genetic heterogeneity in the immunodysregulation, polyendocrinopathy, enteropathy syndrome. J Clin Endocrinol Metab. 2003;88(12):6034–6039.CrossRefPubMedGoogle Scholar
  53. 53.
    Prieur AM, Griscelli C, Lampert F, et al. A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol Suppl. 1987;66:57–68.CrossRefPubMedGoogle Scholar
  54. 54.
    Feldmann J, Prieur AM, Quartier P, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet. 2002;71(1):198–203.CrossRefPubMedGoogle Scholar
  55. 55.
    Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001;29(3):301–305.CrossRefPubMedGoogle Scholar
  56. 56.
    Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 2002;46(12):3340–3348.CrossRefPubMedGoogle Scholar
  57. 57.
    Schuster V, Kreth HW. X-linked lymphoproliferative disease is caused by deficiency of a novel SH2 domain-containing signal transduction adaptor protein. Immunol Rev. 2000;178:21–28.CrossRefPubMedGoogle Scholar
  58. 58.
    Veillette A. Immune regulation by SLAM family receptors and SAP-related adaptors. Nat Rev Immunol. 2006;6(1):56–66.CrossRefPubMedGoogle Scholar
  59. 59.
    Benoit L, Wang X, Pabst HF, Dutz J, Tan R. Defective NK cell activation in X-linked lymphoproliferative disease. J Immunol. 2000;165(7):3549–3553.PubMedGoogle Scholar
  60. 60.
    Nakajima H, Cella M, Bouchon A, et al. Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. Eur J Immunol. 2000;30(11):3309–3318.CrossRefPubMedGoogle Scholar
  61. 61.
    Pasquier B, Yin L, Fondaneche MC, et al. Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J Exp Med. 2005;201(5):695–701.CrossRefPubMedGoogle Scholar
  62. 62.
    Tangye SG, Phillips JH, Lanier LL, Nichols KE. Functional requirement for SAP in 2B4–mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome. J Immunol. 2000;165(6):2932–2936.PubMedGoogle Scholar
  63. 63.
    Worth A, Thrasher AJ, Gaspar HB. Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype. Br J Haematol. 2006;133(2):124–140.CrossRefPubMedGoogle Scholar
  64. 64.
    Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81(6):935–946.CrossRefPubMedGoogle Scholar
  65. 65.
    Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268(5215):1347–1349.CrossRefPubMedGoogle Scholar
  66. 66.
    Le Deist F, Emile JF, Rieux-Laucat F, et al. Clinical, immunological, and pathological consequences of Fas-deficient conditions. Lancet. 1996;348(9029):719–723.CrossRefPubMedGoogle Scholar
  67. 67.
    Chun HJ, Zheng L, Ahmad M, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature. 2002;419(6905):395–399.CrossRefPubMedGoogle Scholar
  68. 68.
    Wang J, Zheng L, Lobito A, et al. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell. 1999;98(1):47–58.CrossRefPubMedGoogle Scholar
  69. 69.
    Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest. 1996;98(5):1107–1113.CrossRefPubMedGoogle Scholar
  70. 70.
    Reeves EP, Lu H, Jacobs HL, et al. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature. 2002;416(6878):291–297.CrossRefPubMedGoogle Scholar
  71. 71.
    Segal BH, Kuhns DB, Ding L, Gallin JI, Holland SM. Thioglycollate peritonitis in mice lacking C5, 5–lipoxygenase, or p47(phox): complement, leukotrienes, and reactive oxidants in acute inflammation. J Leukoc Biol. 2002;71(3):410–416.PubMedGoogle Scholar
  72. 72.
    Malech HL, Hickstein DD. Genetics, biology and clinical management of myeloid cell primary immune deficiencies: chronic granulomatous disease and leukocyte adhesion deficiency. Curr Opin Hematol. 2007;14(1):29–36.CrossRefPubMedGoogle Scholar
  73. 73.
    Helmus Y, Denecke J, Yakubenia S, et al. Leukocyte adhesion deficiency II patients with a dual defect of the GDP-fucose transporter. Blood. 2006;107(10):3959–3966.CrossRefPubMedGoogle Scholar
  74. 74.
    Luhn K, Wild MK, Eckhardt M, Gerardy-Schahn R, Vestweber D. The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter. Nat Genet. 2001;28(1):69–72.CrossRefPubMedGoogle Scholar
  75. 75.
    Ambruso DR, Knall C, Abell AN, et al. Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation. Proc Natl Acad Sci U S A. 2000;97(9):4654–4659.CrossRefPubMedGoogle Scholar
  76. 76.
    Williams DA, Tao W, Yang F, et al. Dominant negative mutation of the hematopoietic-specific Rho GTPase, Rac2, is associated with a human phagocyte immunodeficiency. Blood. 2000;96(5):1646–1654.PubMedGoogle Scholar
  77. 77.
    Abdel-Latif D, Steward M, Macdonald DL, Francis GA, Dinauer MC, Lacy P. Rac2 is critical for neutrophil primary granule exocytosis. Blood. 2004;104(3):832–839.CrossRefPubMedGoogle Scholar
  78. 78.
    Halford WP, Maender JL, Gebhardt BM. Re-evaluating the role of natural killer cells in innate resistance to herpes simplex virus type 1. Virol J. 2005;2:56.CrossRefPubMedGoogle Scholar
  79. 79.
    Vollstedt S, Arnold S, Schwerdel C, et al. Interplay between alpha/beta and gamma interferons with B, T, and natural killer cells in the defense against herpes simplex virus type 1. J Virol. 2004;78(8):3846–3850.CrossRefPubMedGoogle Scholar
  80. 80.
    Vollstedt S, Franchini M, Alber G, Ackermann M, Suter M. Interleukin-12– and gamma interferon-dependent innate immunity are essential and sufficient for long-term survival of passively immunized mice infected with herpes simplex virus type 1. J Virol. 2001;75(20):9596–9600.CrossRefPubMedGoogle Scholar
  81. 81.
    Zawatzky R, Gresser I, DeMaeyer E, Kirchner H. The role of interferon in the resistance of C57BL/6 mice to various doses of herpes simplex virus type 1. J Infect Dis. 1982;146(3):405–410.PubMedGoogle Scholar
  82. 82.
    Niehues T, Reichenbach J, Neubert J, et al. Nuclear factor kappaB essential modulator-deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia. J Allergy Clin Immunol. 2004;114(6):1456–1462.CrossRefPubMedGoogle Scholar
  83. 83.
    Puel A, Reichenbach J, Bustamante J, et al. The NEMO mutation creating the most-upstream premature stop codon is hypomorphic because of a reinitiation of translation. Am J Hum Genet. 2006;78(4):691–701.CrossRefPubMedGoogle Scholar
  84. 84.
    Casrouge A, Zhang SY, Eidenschenk C, et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science. 2006;314(5797):308–312.CrossRefPubMedGoogle Scholar
  85. 85.
    Brinkmann MM, Spooner E, Hoebe K, Beutler B, Ploegh HL, Kim YM. The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling. J Cell Biol. 2007;177(2):265–275.CrossRefPubMedGoogle Scholar
  86. 86.
    Yang K, Puel A, Zhang S, et al. Human TLR-7–, -8–, and -9–mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity. 2005;23(5):465–478.CrossRefPubMedGoogle Scholar
  87. 87.
    Zhang SY, Jouanguy E, Ugolini S, et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science. 2007;317(5844):1522–1527.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • John F. Bastian
    • 1
  • Michelle Hernandez
    • 2
  1. 1.Department of PediatricsUniversity of CaliforniaSan Diego, La JollaUSA
  2. 2.Department of PediatricsUniversity of North CarolinaChapel HillUSA

Personalised recommendations